ADPKD — Tolvaptan and Indications

Genetic GNmedium

A 36-year-old man with ADPKD (PKD1 mutation confirmed) has eGFR 72 mL/min and total kidney volume (TKV) of 2,100 mL (adjusted for height: htTKV 1,350 mL/m, Mayo Imaging Class 1D). He has no prior liver cysts and no hyponatremia. He drinks 2L of water daily. His physician considers tolvaptan. Which statement best describes the evidence and patient selection for tolvaptan in ADPKD?

  1. A.Tolvaptan is indicated for all patients with ADPKD regardless of stage, start at diagnosis
  2. B.Tolvaptan is for rapidly progressive ADPKD (Mayo Class 1C/1D/1E), not for liver disease patientsCorrect
  3. C.Tolvaptan is contraindicated in any patient with PKD1 mutations, only PKD2 benefit
  4. D.Tolvaptan replaces blood pressure management in ADPKD, ACEi/ARB is no longer needed

Explanation

Tolvaptan (Jynarque) is an oral V2 vasopressin receptor antagonist that reduces cAMP-driven cyst epithelial cell proliferation and fluid secretion. Evidence: (1) TEMPO 3:4 trial (Torres et al., NEJM 2012): tolvaptan vs placebo in ADPKD patients at risk of rapid progression (TKV >750 mL) → 49% reduction in TKV growth, 26% slower eGFR decline; (2) REPRISE trial (Torres et al., NEJM 2017): patients with eGFR 25–65 + evidence of rapid progression → tolvaptan slowed eGFR decline by 1.27 mL/min/year; (3) FDA approved (2018) for adults at risk for rapidly progressive ADPKD. Patient selection, rapidly progressive ADPKD: (a) Mayo Imaging Class 1C, 1D, or 1E (htTKV ≥600, ≥900, ≥1500 mL/m respectively at various ages); (b) PROPKD score ≥7 (genetic variant: truncating PKD1 = highest risk); (c) eGFR decline >2.5–5 mL/min/year; this patient has htTKV 1350 mL/m (Class 1D) at age 36 = high-risk → tolvaptan indicated. Safety: (1) Hepatotoxicity: idiosyncratic liver toxicity (elevated ALT/AST), BLACK BOX WARNING; contraindicated in hepatic disease; monthly liver tests required; (2) Aquaretic side effects: polyuria (4–6 L/day), nocturia, thirst, require high fluid intake (≥3L/day) to avoid hypernatremia; (3) Hypernatremia risk if fluid intake inadequate; (4) Avoid volume depletion, hypotension.

Why each option

A.
Incorrect. Tolvaptan is not for all ADPKD, only for patients at risk of rapid progression (Mayo Class 1C/D/E or equivalent PROPKD score). Patients with slow progression have minimal benefit but still carry hepatotoxicity risk.
B.
Correct. Tolvaptan in rapidly progressive ADPKD (Mayo 1C/D/E). TEMPO 3:4: 49% less TKV growth. REPRISE: slows eGFR decline. Hepatotoxicity warning. Requires high fluid intake.
C.
Incorrect. Tolvaptan benefits both PKD1 and PKD2 mutations in rapidly progressive disease. PKD1 truncating mutations carry higher risk, making them more likely to qualify, but the drug works in both.
D.
Incorrect. Tolvaptan does not replace antihypertensive therapy. HALT-PKD trial showed that intensive BP control (ACEi + ARB dual blockade reduced TKV growth in early ADPKD). Tolvaptan is an add-on, not a replacement for BP management.

Reference: Torres VE, NEJM 2012 (TEMPO 3:4); Torres VE, NEJM 2017 (REPRISE); Cornec-Le Gall E, Mayo Classification JASN 2016

This is one of 1,100 questions in the MedBoardSA nephrology bank, with timed test mode, tutor mode, and progress tracking by topic.

Practise the full bank

More Genetic GN questions

Browse other topics